Reservoirs of HIV-1-infected cells persist long-term despite highly effective antiretroviral suppression therapy and represent the main barrier against a cure for HIV-1. This review summarizes recent advances in understanding the complexity and diversity of viral reservoir cells.
INTRODUCTION
The introduction of potent antiretroviral combination therapy (ART) has transformed HIV-1 infection into a manageable chronic disease that remains associated with increased immune activation and other immunological abnormalities, but in many cases does not compromise life quality or expectancy. Nevertheless, ART does not eliminate all HIV-infected cells from the human body, meaning that lifelong suppressive therapy is the only therapeutic option for infected individuals. Characterizing residual reservoirs of virally infected cells that persist despite treatment represents a major focus area within the HIV research community and is frequently considered as an essential prerequisite for efforts to induce a long-lasting, drug-free remission or cure of HIV-1 infection. Current concepts suggest that these viral reservoirs mainly consist of latently infected CD4 T cells that encode for sequence-intact, replication-competent proviruses but exhibit minimal or no active viral gene expression during continuous antiretroviral therapy. However, once ART is interrupted, these latently infected cells can fuel rebound viral replication and lead to high-level viremia, frequently within as few as 2 weeks. The remarkable stability of this viral reservoir, calculated to have a half-life of about 44 months, remains a perplexing aspect of HIV disease pathogenesis. Increasingly, it is recognized that maintenance of this viral reservoir does not simply reflect a protracted or delayed decay of a fixed number of virally infected cells, but represents a highly dynamic process that takes advantage and exploits complex immune mechanisms designed to sustain life-long persistence of cellular immune memory. In this article, we review recent progress in understanding the complexity and diversity of cells that can serve as viral reservoirs, discuss proposed mechanisms and molecular pathways
CELLULAR AND TISSUE RESERVOIRS
Many studies concur that memory CD4 T cells contain the vast majority of persisting proviruses in ART-treated HIV-1 patients, arguably because these cells are susceptible to HIV infection, whereas being able to flexibly fine-tune the level of viral gene expression, possibly as part of a 'bet-hedging' strategy [1] . For instance, during the transition from an activated to a resting state, these cells initiate a transcriptional program that enables viral preintegration steps but restricts active viral gene expression [2] , and for that reason is particularly conducive to supporting viral latency; this may in part explain the preference for memory T cells as long-term viral reservoirs. Nevertheless, the overall frequency of latently infected cells within the memory CD4 T cell pool is extremely small, frequently estimated at around one in a million cells, and the ability to support viral persistence seems to vary considerably among different subsets of the CD4 T memory cell pool. In a provocative recent study, Descours et al. ] compared the transcriptome of HIV-1-infected and HIV-1-uninfected CD4 T cells in a model of HIV-1 latency based on in vitro infection of resting CD4 T cells after experimental downregulation of the HIV-1 restriction factor SAM domain and HD domaincontaining protein 1. Out of 103 differentially expressed genes, the authors identified the gene encoding for CD32a, a member of the Fc Receptor family, as a marker that strongly distinguished infected and uninfected cells. Quantitative viral outgrowth assay (VOA) suggested that CD32aþ CD4 T cells from ART-treated patients were highly enriched for inducible replication-competent proviruses, by a factor of up to 3000-fold compared with total CD4 T cells. Notably, several of the CD32a-positive CD4 T cells appeared to harbor more than one provirus. Significantly, a strong enrichment (up to eight-fold) with chromosomally integrated HIV-1 proviruses was also noticed for cells expressing a combination of the exhaustion markers programmed cell death protein 1, lymphocyte-activation gene 3 and T-cell immunoreceptor with Ig and ITIM domains [4] . If confirmed in futures studies, these studies may provide useful biomarkers for analyzing, monitoring and possibly therapeutically targeting viral reservoirs.
Based on an original study showing that T cells with a T follicular helper cell profile can serve as a predominant viral reservoir cell population in lymph nodes [5 && ,6], subsequent studies have explored how the functional polarization of T cells influences their ability to serve as a viral reservoir. Notably, regulatory T cells seem to be able to serve as a viral reservoir, although more definitive evidence is necessary to fully appreciate their role as viral reservoirs in humans [7 && ,8,9] . Th17 cells, predominantly located in mucosal surfaces and endowed with key roles for antibacterial and antifungal immune defense, seem highly susceptible to HIV, in part due to elevated expression of CC-chemokine receptor 5 (CCR5) and the HIV coreceptor alpha4/b7 and lower expression of ribonucleases with antiviral activity [10, 11] , but their role as a site for persistence of viral reservoirs is less clear. In one study that was limited to peripheral blood lymphocytes, Th17 cells from ART-treated patients did indeed harbor intact proviruses; however, their relative frequency was lower compared with Th1 cells, and not statistically different from the number of proviruses in Th9 and Th2 cells [12 & ]. Given that a large proportion of the viral reservoir is likely to reside in gut-associated lymphoid tissues [13] , a dedicated investigation and characterization of proviral sequences in Th17 cells from mucosal intestinal tissues in ARTtreated patients is a high priority for future studies. A summary of T cell subsets serving as preferential viral reservoir sites is included in Table 1 .
VIRAL NON-CD4 T CELL RESERVOIRS
Although CD4 T cells represent the only cell compartment for which long-term persistence of HIV-1 has been unequivocally proven, there is increasing interest in defining potential non-CD4 T cell reservoirs for HIV-1. For instance, Sebastian et al. [14] recently examined bone-marrow-derived hematopoietic stem cells from ART-suppressed patients and reported
KEY POINTS
Specific subsets of CD4 T cells seem highly enriched with proviral HIV-1 DNA encoding for replicationcompetent HIV-1.
Clonal expansion of CD4 T cells harboring intact proviral DNA is an important mechanism to stabilize long-term persistence of viral reservoir cells.
Increasing evidence suggests that non-CD4 T cells can also serve as niches for persistence of HIV reservoirs.
No interventions are currently available to reliably reduce the number of viral reservoir cells, but multiple different approaches are being evaluated in proof-ofconcept clinical trials.
detection of near full-length HIV DNA in highly enriched progenitor cells. Cell purity analysis demonstrated that this viral DNA was unlikely to derive from contaminating CD4 T cells. Notably, proviral HIV-1 sequences were enriched in a subset of more committed hematopoietic progenitor cells that express high levels of CD4 and seem to be able to support both CCR5 or C-X-C chemokine receptor type 4 tropicinfection. Phylogenetic viral sequencing studies revealed the presence of identical viral HIV envelope protein sequences in progenitor cells and multiple more differentiated hematopoietic lineages, supporting the hypothesis that proliferation and differentiation of infected hematopoietic progenitor cells is a potential mechanism contributing to HIV-1 longterm persistence. In contrast, prior studies have failed to confirm the presence of HIV-1 sequences in more primitive hematopoietic stem cells. A high level of uncertainty exists regarding the role of monocytes and other CD4-cell expressing myeloid cells as potential viral reservoirs. To address this, Honeycutt et al. used a humanized myeloid-only mice (MoM) model, in which only myeloid and B cells are systemically reconstituted with human cells as the host animal (nonobese diabetic/severe combined immunodeficiency/ SCID mice) cannot support human T-cell development. Plasma viral load was successfully suppressed during ART treatment, but a part of the infected MoM (33%, n ¼ 3) displayed rebound viremia after treatment interruption [15 && ]. Based on these results, the authors estimated that infected macrophages in MoM had a rather short half-life (1.05 days as compared with 2.4 days in HIV-1-infected CD4 T cells), and that their number would decay to about 1% after 1 week of ART. The results reinforce the contribution of T cell as the predominant HIV-1 reservoir cell population during long-term ART treatment, but also indicate that at least in principle, macrophage can carry intact provirus during suppressive antiretroviral therapy. To what extent viral persistence in monocytes occurs under physiological conditions in ART-infected humans remains an ongoing question for future studies.
MECHANISMS OF PERSISTENCE
Considerable progress has been made recently in understanding the mechanisms that enable and drive the long-term persistence of viral reservoirs. Lorenzo-Redondo et al. [16] proposed that ongoing viral replication in lymphoid tissues with insufficient antiretroviral drug penetration may support viral persistence, based on viral sequencing results in three individuals analyzed during the first 6 months of antiretroviral therapy; however, such short-term treatment durations might be insufficient to investigate the role of ongoing viral replication for persistence of viral reservoirs [17, 18] . Using a variety of different approaches, a series of recent studies have shown that clonal proliferation of CD4 T cells, a mechanism during which identical proviral copies are passed on from dividing cells to daughter cells, plays a critical role for preserving and amplifying viral reservoirs. For instance, Hosmane et al. & ] employed a near full-length next-generation viral sequencing approach to identify clusters of intact proviruses that were completely identical over the entire near full-genome sequence. Such intact, clonally expanded sequences also accounted for approximately 50-60% of all intact sequences, were longitudinally detectable for a duration of up to 5 years, were preferentially observed in Th1 cells and were fully replication-competent and infectioncompetent. Together, these studies show that viral reservoirs do not consist of a fixed number of virally infected cells, but are replenished or expanded by ongoing proliferation of infected T cells. Whether proliferation of such T cell occurs in response to antigenic stimuli, that is as a by-product of physiologic antigen-specific T-cell proliferation, as a consequence of homeostatic, T cell receptor-independent proliferative signals or through other mechanisms is not fully known. Notably, it is PD-1/LAG-3/TIGIT Exhausted T cells [4] CCR5, CC-chemokine receptor 5; CTLA-4, T-lymphocyte associated protein 4; LAG-3, lymphocyte-activation gene 3; PD-1, programmed cell death protein 1; TIGIT, T-cell immunoreceptor with Ig and ITIM domains.
conceivable that the chromosomal integration of intact proviruses in genes governing and driving T-cell proliferation may result in selective expansions of the respective cell clone, as suggested by some experimental findings [22] . Clonal proliferation is known to be a highly vulnerable step in a cell's life cycle, suggesting that specific molecular mechanisms protect and safeguard HIV-1-encoding CD4 T cells during this process. In this context, several studies suggest that expression of antiapoptosis molecules, previously mostly recognized for their role in maintaining reservoirs of treatment-resistant cancer cells in malignant diseases, are involved in preserving survival of viral reservoirs. ]. In contrast to VOA, it allows to quantify the relative proportion of intact and defective proviruses, can identify clusters of clonally expanded proviruses, and also provides some information about immune-driven or antiretroviral drug-driven viral sequence variation, although its rather costly and labor-intensive nature is a concern. Detection of cell-associated HIV-1 RNA by in-situ hybridization, followed by flow cytometric visualization, was most comprehensively demonstrated by Baxter et al. [35 & ] but also explored by others [36, 37] , and may provide for an elegant approach to analyze cells expressing viral RNA after latency reversal. To what extent cellular expression of viral RNA detected by this approach reflects the presence of replication-competent viral sequences needs to be studies in future work.
METHODS FOR QUANTIFYING VIRAL RESERVOIRS

CLINICAL APPROACHES FOR VIRAL RESERVOIR REDUCTION
Most clinical efforts to reduce viral reservoirs focus on the shock and kill strategy, which is based on the assumption that pharmacological reactivation of viral gene expression results in immune-mediated elimination of virally infected cells; recent studies do suggest that triggering of viral antigen expression through latency-reversing agents (LRA) is indeed sufficient in quantity and duration to allow recognition and clearance of such cells, at least in in vitro assays [38] . Several recently conducted clinical studies have shown that induction of proviral gene expression by histone deacetylase inhibitors [39] and toll-like receptor 9 ligands [40] is possible without inducing generalized immune activation [41] ; however, such efforts have failed so far to translate into pronounced reductions of viral reservoir size, even when combined with therapeutic vaccines designed to activate HIV-1-specific T cells [42] . Notably, in vivo studies demonstrated that reactivation of viral gene expression from latency by pharmacological inducers critically depends on the chromosomal position of integrated proviruses [43 && ], implying that development of a 'one-size-fits-all'-type of latency reversing agent may not be feasible; instead, combinations of different LRA may be required to mobilize the entire spectrum of integrated proviruses. Significantly, initial cell culture assays demonstrated that pharmaceutical inhibitors of lens epithelium-derived growth factor/p75, a host factor responsible for driving HIV-1 integration into actively transcribed regions of the genome, may allow to steer viral genomes into chromosomal segments that do not effectively support viral gene transcription [44] . Such an approach, specifically when combined with pharmacological inhibitors of the viral transactivation protein transactivator of transcription protein that can silence HIV-1 gene expression [45] , may allow to induce a state of 'deep latency' that may enable some degree of spontaneous ART-free viral control. Notably, unselective killing of CD4 T cells during cytotoxic chemotherapy was paradoxically associated with increased levels of CD4 T cell-associated HIV-1 DNA and RNA, possibly as a result of clonal expansion of HIV-1-infected cytomegalovirus-specific or Epstein-Barr virus-specific CD4 T cells [46] . In contrast, a relatively long remission of HIV-1 replication during an analytical treatment interruption was noticed in an HIV-1-infected recipient of an allogeneic bone marrow transplant [47] ; this and other similar cases [48] suggest that such a therapeutic approach is likely to induce more complex changes in the reservoir structure, and deserve further investigation.
CONCLUSION
The remarkable ability of HIV-1 to persist in the human body despite decades of highly effective antiretroviral therapy arguably represents the most perplexing and irritating aspect of HIV disease pathogenesis. Recent studies emphasize the complexity of the viral reservoir and highlight that viral eradication or a 'sterilizing cure' of HIV-1 infection remains a daunting task. Nevertheless, there is undeniable progress in understanding the cell compartments and the biological mechanisms contributing to persistence of long-lived viral reservoirs. The authors of this article remain hopeful that increased insight into the structure and composition of viral reservoir cells will ultimately allow to transform HIV-1 infection into a curable disease. 
